cagrilintide – Medxy AI

Cagrilintide-Semaglutide (CagriSema) Lowers HbA1c Better Than Semaglutide Alone in Type 2 Diabetes

By MedXY 06/10/2026

REIMAGINE 2 found that once-weekly cagrilintide-semaglutide lowered HbA1c more than semaglutide alone in adults with type 2 diabetes and overweight or obesity, with a safety profile consistent with known gastrointestinal effects.

Clinical Updates news

CagriSema for Early Type 2 Diabetes: Interpreting the Phase 3a REIMAGINE 1 Trial in the Context of Incretin–Amylin Combination Therapy

By MedXY 06/09/2026

REIMAGINE 1 shows that once-weekly CagriSema significantly reduced HbA1c and bodyweight versus placebo in early type 2 diabetes, with mainly gastrointestinal adverse events and a mechanistically compelling incretin–amylin profile.

Diabetes & Endocrinology Specialties

Cagrilintide-Semaglutide Combination Shows Promising Efficacy for Weight and Glycemic Control in Adults with Type 2 Diabetes and Obesity

By MedXY 09/07/2025

A 68-week phase 3a trial demonstrates that once-weekly cagrilintide-semaglutide significantly reduces body weight and improves glycemic control compared to placebo in adults with overweight or obesity and type 2 diabetes, with good tolerability.

Diabetes & Endocrinology Specialties

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

By MedXY 08/28/2025

A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option for obesity management.

Diabetes & Endocrinology news Specialties

Advances in Obesity and Diabetes Management: Highlights from ADA 2025

By MedXY 07/31/2025

New weight-loss drug combinations, oral semaglutide cardiovascular outcomes, inhaled insulin for type 1 diabetes, and benefits of switching from diet drinks to water were key ADA 2025 findings.